THE PATENTS ACT, 1970 COMPLETE SPECIFICATION Section 10 "A Compound of Formula I haying an Activity to Inhibit Matrix Metalloproteinases" Abbott Laboratories, U.S.A. a corporation organized and existing under the laws of Illinois, of 100, Abbott Park Road, Abbott Park, Illinois 60064-6008, USA. GRANTED 9-8-2007 The following specification particularly describes the nature of this invention and the manner in which it is to be performed: ORIGINAL IN/PCT/2001/747/MUM (1) hydrogen, and (2) alkyl, or R3 and R4 taken together are oxo, or R3 and R4 , taken together with the carbon atom to which they are attached, form a cycloalkyl ring; R5 and R6 are independently selected from the group consisting of (l)hydrogen, (2) alkyl, (3) perfmoroalkyl, (4) halo, (5) haloalkyl, (6) alkoxy, (7) hydroxy, (8) hydroxyalkyl, (9) alkoxyalkyl, and (10) nitro; Y is selected from the group consisting of (l)acovalentbond, (2)-O-, (3) alkylene of two to four carbon atoms, (4) piperidineneyl, (5) alkenylene of two carbon atoms, (6) alkynylene of two carbon atoms, (7)-S02-, and (8)-C(0)-; Ar is selected from the group consisting of (1) phenyl, (2) pyridyl, Technical Field This invention relates to compounds having activity to inhibit matrix metalloproteinases, to pharmaceutical compositions comprising these compounds, and to a medical method of treatment. More particularly, this invention concerns reverse hydroxamate-containing compounds which inhibit matrix metalloproteinases, pharmaceutical compositions comprising the compounds, and methods of inhibiting matrix metalloproteinases in a mammal. Background of the Invention The matrix metalloproteinases (MMP's) are a class of extracellular enzymes including collagenase, stromelysin, and gelatinase which are believed to be involved in the tissue destruction which accompanies a large number of disease states varying from arthritis to cancer. Typical connective tissue cells are embedded within an extracellular matrix of high molecular weight proteins and glycoproteins. In healthy tissue, there is a continual and delicately-balanced series of processes which include cell division, matrix synthesis and matrix degradation. In certain pathological conditions, an imbalance of these three processes can lead to improper tissue restructuring. In arthritis, for example, joint mobility can be lost when there is improper remodeling of load-bearing joint cartilage. With cancer, lack of coordination of cell division and the two processes of matrix synthesis and degradation may lead to conversion of transformed cells to invasive phenotypes in which increased matrix turnover permits tumor cells to penetrate basement membranes surrounding capillaries which, in turn, may lead to subsequent metastasis. There has been heightened interest in discovering therapeutic agents which bind to and inhibit MMP's. The discovery of new therapeutic agents possessing this activity will lead to new drugs having a novel mechanism of action for combating disease states involving tissue degenerative processes including, for example, rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodontitis, gingivitis, corneal, epidermal or gastric ulceration, and tumor growth and metastasis or invasion. This invention discloses a series of MMP inhibitors having a unique combination of potency, pharmacokinetics, and fewer side effects. Summary of the Invention In its principle embodiment, the present invention provides a matrix metalloproteinase inhibitory compound of formula (I), or a pharmaceutical] y acceptable salt or prodrug thereof, wherein W is selected from the group consisting of (l)-O-, (2)-CH20-, and (3)-CH2s wherein each group is drawn with its left-hand end being the end which attaches to the carbon containing R1 and R2, and its right-hand end being the end which attaches to the carbon containing R and R ; X is selected from the group consisting of (l)-O-, and (2) -N(R7)-, wherein R7is selected from the group consisting of (a) hydrogen, (b) alkyl, (c) -S02-alkyl, and (d) alkanoyl; R1 and R2 are independently selected from the group consisting of (1) hydrogen, (2) alkyl, and (3) hydroxyalkyl; R3and R4 are independently selected from the group consisting of (3) pyrazinyl, (4) pyridazinyl, (5)furyl, (6) thienyl, (7) isoxazolyl, (8) oxazolyl, (9) thiazolyl, and (l0)isothiazolyl, wherein (1)-(10) can be optionally substituted with one, two, or three substituents independently selected from the group consisting of (a)alkyl, (b) alkoxy, wherein the alkoxy can be optionally substituted with alkoxy, (c) -(alkylene)-CC>2R8 , wherein R8 is either hydrogen or alkyl, (d) -(alkylene)-NR 9R10 , wherein R9 and R10 are independently selected from the group consisting of (i) alkyl, (ii) phenyl, and (iii) phenylalkyl, wherein for (ii) and (iii), the phenyl and the phenyl part of die phenylalkyl can be optionally substituted with one or two substituents independently selected from the group consisting of halo and alkoxy, (e) alkoxyalkyl, (f) cyano, (g) cyanoalkyl, (h)halo, (i) haloalkyl, (j) hydroxy, (k) hydroxyalkyl, (1) thioalkoxy, (m) thioalkoxyalkyl, (n) phenylalkoxy, (o) phenoxy, (p) phenoxyalkyl, (q) (heterocycle)oxy, (r) (heterocycle)oxyalkyl, (s) perfluoroalkyl, (t) perfluoroalkoxy, (u) sulfmylalkyl, (v) sulfonylalkyl, (w) , wherein A is selected from the group consisting of -CH2-, -CH2O- and -O-, and B is selected from the group consisting of -C(O)- and -2,2-dimethyl-l,3-dioxolane-4-carboxylate for methyl (4R)-2,2-dimethyl-l,3-dioxolane-4-carboxylate in Examples 1A-1E. MS (ESI) m/z 506 (M+H)+; 'H NMR (300 MHz, DMSO-dfi): 5 1.21 (s, 1.5H), 1.23 (s, 1.5H), 1.26 (s, 1.5H), 1.30 (s, 1.5H), 3.3-3.4 (m, 1H), 3.60-3.75 (m, 2H), 3.9-4.1 (m, 2.5H), 4.5-4.6 (m, 0.5H), 7.2-7.3 (m, 4H), 7.48 (d, 2H, J=8.7 Hz), 7.81 (s, 0.5H), 7.85-7.95 (m, 2H), 8.13 (s, 0.5H), 9.63 (br s,0.5H), 10.0(brs,0.5H); Anal. Calcd. for C21H22F3N08S: C, 49.90; H, 4.38; N, 2.77. Found: C, 49.90; H, 4.51; N, 2.66. Example 3C (lR)-l-(f4RV2.2-dimethvl-1.3-dioxolan-4-vlV2-((4-(4-(trifluoromethoxv)phenoxv)phenvl)sulfonvl)ethvl(hvdroxy)formamide The desired product was prepared by substituting Example 3B for Example IE in Example 2. Example 4 (1S)-l-((4RV2.2-dimethvl-1.3-dioxolan-4-vn-2-((4-r4-(trifluoromethoxv)phenoxv)phenvl)sulfonvl)ethyl(hvdroxv¥ormamide The desired product was prepared by substituting Example 3A for Example ID in Example IF. MS (ESI) m/z 506 (M+H)+; 'H NMR (300 MHz, DMSO-d6): 1.05 (s, 1.5H), 1.14 (s, 1.5H), 1.20 (s, 1.5H), 1.23 (s, 1.5H), 3.3-3:4 (m, 1H), 3.5-4.1 (m, 4.5H), 4.3-4.4 (m, 0.5H), 7.2-7.3 (m, 4H), 7.48 (d, 2H), 7.8-8.0 (m, 2.5H), 8.15 (s, 0.5H), 9.68 (br s, 0.5H), 10.10 (br s, 0.5H). £0 Example 5 Example 5A 4'-chIorof 1.1 '-biphenvlV4-vl methyhulfone The desired product was prepared by substituting 4-chlorophenylboronic acid for 4-trifluoromethylphenylboronic acid in Example 12A. Example 5B The desired product was prepared by substituting Example 5A for 4-(4'-trifluoromethoxyphenoxyjphenyl methyl sulfone in Example 1. MS (ESI) m/z 440 (M+H)+; !H NMR (DMSO-dg): 5 1.20 (s, 1.5H), 1.22 (s, 1.5H), 1.26 (s, 1.5H), 2.30 (s, 1.5H), 3.32-3.40 (m, 1H), 3.62-3.78 (m, 2H), 3.93-4.15 (m, 2.5H), 4.64 (t, 0.5H, J=8.4 Hz), 7.58 (d, 2H, J=8.4 Hz), 7.77-7.83 (m, 2H), 7.89 (s, 0.5H), 7.93-8.02 (m, 4H), 8.13 (s, 0.5H), 9.62 (bs, 0.5H), 9.97 (bs, 0.5H); Anal. Calcd. for C20H22NO6SCI: C, 54.60; H, 5.04; N, 3.18. Found: C, 54.48; H, 5.30; N, 3.13. Example 6 (trifluoromethoxy)phenoxy)phenvl)suulfonvl)ethvl(hvdroxy)formamide Example 6A A solution of Example 1A (1.0 g, 3.0 mmol) in THF (50 mL) at -78 °C was treated with n-butyllithium (2.5M in hexanes, 1.3 mL, 3.3 mmol) and stirred for 1.5 hours. The solution was added by cannula to a -78 °C solution of (R)2,2-diethyl-l,3-dioxolane-4-carboxaldehyde (0.95 g, 6.0 mmol) (prepared according to the procedure described in Synthesis, 1992, p. 587) in THF (10 mL), stirred for 3 hours, treated with saturated NH4C1, and extracted with ethyl acetate. The combined extracts were washed with brine, dried (MgSO4), filtered, and concentrated. The concentrate was purified first by flash column chromatography on silica gel with 3:l/hexanes:ethyl acetate to 3:2/hexanes:ethyl acetate, then by HPLC with 3:2/hexanes:ethyl acetate to provide the desired product as a mixture of diasteieomers. Example 6B The desired product was prepared by substituting Example 6 A for Example IB in Example 1C (omitting the sodium borohydride reduction), then substituting the resulting product for Example 1C in Examples 1D and 1F. MS (ESI) m/z 534 (M+H)+; 1H NMR (300 MHz, DMSO-d6): 5 0.7-0.8 (m, 6H), 1.4-1.6 (m, 4H), 3.2-3.3 (m, 1H), 3.45-3.55 (m, 1H), 3.69 (dd, 1H, J=8.7,15.6 Hz), 3.95-4.15 (m, 2.5H), 4.5-4.6 (m, 0.5H), 7.2-7.3 (m, 4H), 7.47 (d, 2H, J=8.4 Hz), 7.81 (s, 0.5H), 7.85-7.95 (m, 2H), 8.14 (s, 0.5H), 9.66 (br s, 0.5H), 10.11 (br s, 0.5H); Anal. Calcd for C23H26NO8SF3: C, 51.77; H, 4.91; N, 2.62. Found: C, 51.98; H, 5.12; N, 2.63. The desired product was prepared by substituting methyl 3,4-isopropylidene-L-threonate for methyl (R)-2,2-dimethyl-l,3-dioxolane-4-carboxylate in Example 1. MS (ESI) m/z 520 (M+H)+; 'H NMR (300 MHz, DMSO-d6): 6 1.2-1.3 (m, 9H), 3.3-3.5 (m, 2H), 3.6-3.9 (m, 3H), 4.1- 4.2 (apparent t, 0.5H, J=5.0 Hz), 4.6-4.7 (apparent t, 0.5H, J=5.0 Hz), 7.2-7.3 (m, 4H), 7.48 (d, 2H, J=9.0 Hz), 7.85-8.00 (m, 2.5H), 8.15 (s, 0.5H), 9.69 (s, 0.5H), 9.95 (s, 0.5H); Anal. Calcd. for C22H24NO8SF3: C, 50.86; H, 4.65; N, 2.69. Found: C, 51.01; H, 4.38; N, 2.47. The desired product was prepared by substituting 4-methoxyphenol for 4-trifluoromethoxyphenol in Example 1. 35 1H NMR (DMSO-d6): 5 1.20-1.32 (m, 6H), 3.24-3.35 (m, 1H), 3.58-3.70 (m, 2H), 3.78 (s, 3H), 3.92-4.13 (m, 2.5H), 4.57 (t, 0.5H, J=8.1 Hz), 7.00-7.14 (m, 6H), 7.84 (dd, 2H, J=12.3,2.1 Hz), 7.89 (s, 0.5H), 8.13 (s, 0.5H), 9.64 (s, 0.5H), 10.02 (s, 0.5H); Anal. Calcd. for C21H25N08S: C, 55.87; H, 5.58; N, 3.10. Found: C, 55.72; H, 5.59; N, 2.96. The desired product was prepared by substituting 4-chlorophenol for 4-trifluoromethoxyphenol in Example 1. mp: 157-158 °C; -f-2.2°(c 0.4, CH3OH); MS (ESI) m/z 456 (M+H)+; 'H NMR (DMSO-d6): 1.19-1.33 (m, 6H), 3.28-3.36 (m, 1H), 3.50-3.72 (m, 2H), 3.92-4.13 (m, 2.5H), 4.55 (t, 0.5H, J=8.1 Hz), 7.15-7.24 (m, 4H), 7.49-7.56 (m, 2H), 7.81 (s, 0.5H), 7.90 (t, 2H, J=9.3 Hz), 8.12 (s, 0.5H), 9.62 (s, 0.5H), 10.03 (s, 0.5H); Anal. Calcd. for C20H22NO7SCI: C, 52.69; H, 4.86; N, 3.07. Found: C, 52.67; H, 4.79; N, 2.87. 1 The desired product was prepared by substituting 4-trifluoromethylphenol for 4-trifluoromethoxyphenol in Example 1. mp: 141-143 °C; (a)D+2.0°(c 0.1, CH3OH); MS (APCI) m/z 490 (M+H)+; 'HNMR (DMSO-d6): 8 1.20-1.33 (m, 6H), 3.35-3.41 (m, 1H), 3.62-3.77 (m, 2H), 3.95-4.15 (m, 2.5H), 4.57 (t, 0.5H, J=8 Hz), 7.27-7.35 (m, 4H), 7.77-7.85 (m, 2.5H), 7.91-7.99 (m, 2H), 8.13 (s, 0.5H), 9.50-9.85 (m, 1H); Anal. Calcd. for C21H22F3NO7S: C, 51.53; H, 4.53; N, 2.86 Found: C, 51.60; H, 4.61; N, 2.88. The desired product was prepared by substituting 4-methylphenol for 4-trifluoromethoxyphenol in Example 1. mp: 156-158 °C; (x)D+5.0°(c 0.2, CH3OH); MS (APCI) m/z 436 (M+H)+; lH NMR (DMSO-dfi): 5 1.17-1.36 (m, 6H), 3.21-3.31 (m, 1H), 3.34 (s, 3H), 3.58-3.73 (m, 2H), 3.91-4.16 (m, 2.5H), 4.57-4.64 (m, 0.5H), 6.97-7.06 (m, 2H), 7.10 (d, 2H, J=9 Hz), 7.26 (d, 2H, J=9 Hz), 7.78-7.93 (m, 2.5H), 8.13 (s, 0.5H), 9.41-10.12 (bs, 1H); Anal. Calcd. for C21H25NO7S: C, 57.92; H, 5.79; N, 3.22;S,7.36. Found: C.57.63; H, 5.81; N, 3.11;S,7.21. A solution of 4-(trifluoromethyl)phenylboronic acid (12.0g, 62 mmol) and 4-bromophenyl methyl sulfone (14.93g, 62 mmol) in DMF (200 mL) was treated with Cs2C03 (61g, 187 mmol) and PdCl2(dppf)2 (1.5g), heated to 60 °C, stirred for 3 hours, cooled to room temperature, and stirred for 16 hours. The mixture was partitioned between ethyl acetate and water and the organic phase was washed sequentially with l:l/brine:water and brine, dried (Na2SO4), filtered, and concentrated. The concentrate was recrystallized from ethyl acetate/hexanes to provide the desired product. MS (APCI) m/z 318 (M+NH4)+ The desired product was prepared by substituting Example 12A for Example 1A in Examples 1B-1F. mp: 204-205 °C; (x)D+6.0°(c 0.1, CH3OH); MS (ESI) m/z 474 (M+H)+; >H NMR (DMSO-de): 5 1.13-1.42 (m, 6H), 3.35-3.48 (m, 1H), 3.62-3.85 (m, 2H), 3.93-4.24 (m, 2.5H), 4.61-4.76 (m, 0.5H), 7.79-8.27 (m, 9H), 9.79-10.20 (m, 1H); Anal. Calcd. for C2,H22F3N06S: C, 53.27; H, 4.68; N, 2.96; S, 6.77; F, 12.04. Found: C, 53.09; H, 4.74; N, 2.89; S, 6.79; F, 12.21. Example 13 A solution of Example 1C (760 mg, 0.95 mmol) in THF (15mL) was treated with 3N HC1 (3 mL), heated to 45 °C, stirred for 1.5 hours, cooled to room temperature, and extracted with diethyl ether. The combined extracts were washed with brine, dried (Na2S04), filtered and concentrated to provide the desired product. MS(DCI) m/z 422 (M+NH4)+. A solution of Example 13 A (970 mg) in DMSO (12 mL) at 65 °C was treated with POCb, stirred for 2.5 hours, and partitioned between diethyl ether and water. The organic phase was washed with brine, dried (Na2S04), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel using 9:l/dichlorornethane:hexanes, then dichloromethane, then 9:l/dichloromethane:ethyl acetate to provide the desired product. MS(DCI) m/z 434 (M+NH4)+. The desired product was prepared by substituting Example. 13B for Example IB in Examples 1D and 1F. MS (ESI) m/z 476 (M-HV; 1H NMR (DMSO-de): 6 3.53-4.16 (m, 5.5H), 4.51-4.63 (m, 0.5H), 4.74 (d, 1H, J=12 Hz), 4.84 (s, 0.5H), 4.95 (s, 0.5H), 7.23 (d, 2H, J=9 Hz), 7.28 (d, 2H, J=9 Hz), 7.48 (d, 2H, J=9 Hz), 7.83 (s, 0.5H), 7.94 (dd, 2H, J=9,8.8 Hz), 8.17 (s, 0.5H), 9.15 (s, 0.5H), 10.03 (s, 0.5H); Anal. Caicd. for C19H18NO8SF3. C, 47.80; H, 3.80; N, 2,93. Found: C, 47.55; H, 3.76; N, 2.82. Example 14 The desired product was prepared by substituting 4-(methyIsulfanyl)phenylboronic acid and l-bromo-4-(2-methoxyethoxy)benzene for 4-(trifluoromethyl)phenylboronic acid and 4-bromophenyl methyl sulfone, respectively, in Example 12A. A suspension of Example 14A (2.8g, 10.2 mmol) in 2:l/methanol:water (100 mL) at 0 °C was treated with NaHC03 (2.14g, 25.3 mmol) and oxone (15.7g, 25.3 mmol), stirred for 1 hour, warmed to room temperature, and stirred for 48 hours. The mixture was partitioned between water and dichloromethane and the aqueous phase was extracted with dichloromethane. The combined extracts were washed with brine, dried (Na2SO4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with l:l/hexanes:ethyl acetate to provide the desired product. MS (ESI) m/z 307 (M+H)+. (formyl(hydroxv)amino)ethyl)sulfonvl)4'-(2-methoxyethoxy)-l.r;biphenyl The desired product was prepared by substituting Example 14B for Example 1A in Examples IB-ID and 1F. MS (ESI) m/z 478 (M-HT; 'H NMR (DMSO-do) .21 (d, 3H, J=9 Hz), 1.25-1.35 (m, 3H), 3.28-3.42 (m, 4H), 3.46- 3.57 (m, 1H), 3.10-3.26 (m, 3H), 3.86-4.20 (m, 4H), 4.29-4.45 (m, 0.5H), 4.57-4.68 (m, 0.5H), 7.08 (d, 2H, J=9 Hz), 7.68-7.77 (m, 2H), 7.83-7.97 (m, 4.5H), 8.14 (s, 0.5H), 9.62 (s, 0.5H), 9.98 (s, 0.5H); Anal. Calcd. for C23H29NO8S: C, 57.60; H, 6.09; N, 2.92. Found: C, 57.61; H, 6.10; N, 2.92. Example 15A l-(benzvioxv)-4-f2-methoxvethoxv)benzene A solution of 4-(benzyloxy)phenol (6.1g, 30.5 mmol), 2-methoxyethanol (2.4 mL, 30.5 mmol) and triphenylphosphine (8.78g, 30.5 mmol) in THF (150 mL) at 0 °C was treated with diethylazodicarboxylate (5.3 mL, 33.5 mmol), stirred for 10 minutes, warmed to room temperature, and stirred for 12 hours. The mixture was diluted with ethyl acetate, washed with 2N NaOH and brine, dried (Na2Sd4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 9:l/hexanes:ethyl acetate to provide the desired product Example 15B 4-f2-methoxvethoxyVphenol A solution of Example 15A (4.8 g, 18.6 mmol) in methanol (48 mL) was treated with 20% Pd(OH)2 on carbon (0.48 g) and stirred under 60 psi of hydrogen at 50 °C for 1 hour. The mixture was filtered and the filtrate was concentrated to provide the desired product. MS (DCI) m/z 186 (M+NH4)+. Example 15C (lS)l-((4SV2.2-dimethvl-1.3-dioxolan-4-vl)2-((4-(4-(2-methoxvethoxv)phenoxv)phenvl)sulfonvl)ethvl(hvdroxy)formamide The desired product was prepared by substituting Example 15B for 4-trifluoromethoxyphenol in Example 1. 'H NMR (DMSO-de): 8 1.22 (d, 3H, J=9 Hz), 1.28 (d, 3H, J=12 Hz), 3.22-3.35 (m, 3H), 3.57-3.60 (m, 4H), 3.93-4.15 (m, 5.5H), 4.52-4.63 (m, 0.5H), 7.0-7.13 (m, 6H), 7.83 (d, 0.5H, J=3 Hz), 7.87 (d, 2H, J=10 Hz), 8.12 (s, 0.5H), 9.63 (s, 0.5H), 9.98 (s, 0.5H); Anal. Calcd. for C23H29O9SN: C, 55.74; H, 5.89; N, 2.82. Found: C, 55.65; H, 5.82; N, 2.79. Example 16 1,2.4-trideoxv-2-ffonnvlmvdroxy)aminoxy)-4.4-dimethyl)-3.5-0-(l-methylpthylidene)-l-((4-(4-(trifluoromethoxv)phenoxv)phenvl)sulfonvl)-D-threo-pentitol Example 16 A (3R)3-rrtert-butvl(dimethvl)siIvl)oxv)-5-hvdroxv-4.4-dimethvl-l-((4-(4- (trifluoromethoxy)phenoxy)phenyl)sulfonvl)-2-pentanone The desired product was prepared by substituting (3R)-3-((tert-butyl(dimethyl)silyl)oxy)-4.4-dimethyldihydro-2(3H)-furanone and memyl 4-(4-(trifluoromethoxy)phenoxy)phenyl sulfone for methyl (4R)-2,2-dimethyl-l,3-dioxolane-4-carboxylate and 4-(4'-trifluoromethoxyphenoxy)phenyl methyl sulfone, respectively, in Example 1B. A solution of Example 16A (1.7 g, 2.9 mmol) in THF (10 mL) at 0 °C was treated with tetrabutylammonium fluoride (1M in THF, 8.7 mL, 8.7 mmol), stirred for 1 hour, warmed to room temperature, stirred for 3 hours, and partitioned between ethyl acetate and brine. The organic phase was washed with brine, dried (MgSO4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 65:35/hexanes:ethyl acetate to provide the desired product. A solution of Example 16B (l.lg, 2.4 mmol) and 2,2-propanediol (350 mL) in DMF (10 mL) at room temperature was treated with catalytic camphorsulfonic acid, stirred for 15 hours, and partitioned between water and ethyl acetate. The organic phase was washed with brine, dried (MgS04), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 3:l/hexanes:ethyl acetate to provide the desired product. The desired product was prepared by substituting Example 16C for Example IB in Examples 1C, 1D, and 1F. MS(ESI)m/z 546(M-H)"; 1H NMR (DMSO-de): 6 0.64-0.83 (m, 3H), 0.90 (s, 3H), 1.25-1.33 (m, 6H), 3.03-3.14 (m, 1H), 3.33-3.54 (m, 2H), 3.62-3.72 (m, 1H), 3.73-3.85 (m, 1H), 3.92-4.05 (m, 0.5H), 4.69-4.78 (m, 0.5H), 7.19-7.20 (m, 4H), 7.48 (d, 2H, J=9 Hz), 7.76 (s, 0.5H), 7.88-7.97 (m, 2H), 8.05 (s, 0.5H), 9.28 (s, 1H); Anal. Calcd. for C24H28N08SF3: C, 52.64; H, 5.15; N, 2.55. Found: C, 52.83; H, 5.30; N, 2.30. and The desired product was prepared by substituting methyl (2R)-tetrahydro-2-furancarboxylate for methyl (4R)-2,2-dimethyl-l,3-dioxolane-4-carboxylate in Examples 1A-1E. The desired product was prepared by substituting Example 17A for Example ID in Example 1F. mp: 121-122 °C; =-2.5° (c 1.08, CH3OH); MS (ESI, +Q1MS) m/z 476 (M+H)+; 'H NMR (500MHz, DMSO-d6): 8 1.37-1.45 (m, 1H), 1.71-1.82 (m, 2H), 1.88-1.99 (m, 1H), 3.28 (m, 0.6H), 3.56-3.73 (m, 4H), 3.81-3.91 (m, 2H), 4.46 (t, 0.4H, J=10.0 Hz), 7.22 (d, 2H, J=9.0 Hz), 7.25-7.29 (m, 2H), 7.46 (d, 2H, J=8.5 Hz), 7.77 (s, 0.6H), 7.90 (d, 2H, J=9.0 Hz), 7.93 (d, 2H, J=8.5 Hz), 8.12 (S, 0.4H), 9.45 (s, br, 0.6H), 9.82 (s, br, 0.4H); Anal. Calcd. for C20H20F3NO7S: C, 50.52; H, 4.24; N, 2.95. Found: C, 50.69; H, 4.47; N, 2.89. The desired product was prepared by substituting Example 17B for Example 1E in Example 2. mp: 142.5-143.5 °C; = -23.8° ( +2.0°(c 0.98, CH3OH); MS (ESI, +Q1MS) m/z 476 (M+H)+; 1H NMR (400MHz, DMSO-d6): 5 1.47-3.93 (m, 4H), 3.38-3.93 (m, 5.5H), 4.36 (t, 0.5H, J=8.8 Hz), 7.20-7.30 (m, 4H), 7.46 (d, 2H, J=8.88 Hz), 7.87-7.92 (m, 2.5H), 8.11 (s, 0.5H), 9.63 (s, br, 0.5H), 10.05 (s, br, 0.5H); Anal. Calcd. for: C20H20F3NO7S: C, 50.52; H, 4.24; N, 2.95. Found: C, 50.76; H, 4.34; N, 2.77. A 0 °C; solution of D-proline methyl ester hydrochloride (4.5g, 27mmol) (prepared according to the procedure described in Synthesis, 195,p. 772) in dichloromethane (2Qo mL) at room temperature was treated with triethylamine (11.3 mL, 81 mmol) and methylsulfonyl chloride (3.13 mL, 40 mmol), then stirred for 4 hours. The reaction wa.s partitioned between saturated NH4C1 and dichloromethane, and the organic phase was washed sequentially with saturated NaHCO3) and brine, dried (Na2S04), filtered, and concentrated \Q provide the desired product. MS (DCI) m/* 225 (M+NEUf. The d6,sired product was prepared by substituting Example 19A for methyl (R)-2,2-dimethyl-l,3-dioxolane-4-carboxylate in Example 1. MS (ESI) m/e 553 (M+H)+, 570 (M+NHt)+, 551 (M-H)'; (ά)D:-12.33°C, (CHC13, c 0.3); 'H NMR (30Q MHz, DMSO-d6): 5 1.65-1.78 (m, 3H), 1.93-2.08 (m, 1H), 2.85 (s, 0.4% 2.88 (s, 0.6H), 3.12-3.45 (m, 3H), 3.71-3.79 (m, 0.6H), 4.23-4.28 (m, 0.4H), 7.19-7.29 (m, 4H), 7.43-7.45 (d, 2H, J=8.7 Hz), 7.80 (s, 0.6H), 7.86-7.92 (m, 2H), 8.17 (s, 0.4H), 9.48 (s, 0.6H),9.71(s,o.4H). High resolution MS (FAB) Calc. m/z for (M+H)+ 553.0926, observed m/z 553.0930. The desired product was prepared as a mixture of diastereomers by substituting methyl (4R)-2-oxo-l,3-oxazolidine-4-carboxylate (prepared according to the procedure described in Tet. Lett. 1994, p. 2397) for methyl (R)-2,2-dimethyl-l,3-dioxolane-4-carboxylate in Example 1. MS (ESI +Q1MS) m/z 508 (M+NH4)+; lH NMR (400MHz, DMSO-de): 5 3.42-3.60 (m, 1H), 3.68-400 (m, 3H), 4.05-4.60 (m, 2H), 7.20-7.32 (m, 4H), 7.47 (d, 2H, J=6.6 Hz), 7.80-7.96 (M, 3.5H), 8.15 (S, 0.5H), 9.53 (S, br, 0.25H), 9.71 (S, br, 0.25H), 9.97 (s, br, 0.25H), 10.12 (s, br, 0.25H); Anal. Calcd. for C19H17F3OgS: C, 46.53; H, 3.49; N, 5.71. Found: C, 46.26; H, 3.43; N, 5.57. Example 21 hvdroxv((lRSyi-f(4SV3-methvl-2-oxo-1.3-oxazolidin-4-vlV2-f(4-(4-(trifluoromethoxy)phenoxv)phenvl)sulfonyl')ethvl¥ormamide The desired product was prepared as a mixture of diastereomers by substituting methyl (4R)-3-methyI-2-oxo-l,3-oxazolidine-4-carboxylate for methyl (R)-2,2-dimethyl-l,3-dioxolane-4-carboxylate in Example 1. MS (ESI, Q+1MS) m/z 505 (M+H)+, 522 (M+NH*)*; 'H NMR (400MHz, DMSO-d*): S 2.69 (s, 1.5H), 2.76 (s, 1.5H), 3.54-3.65 (m, IH), 3.79-3.94 (m, 2H), 4.21 (t, IH, J-8.8 Hz), 4.27-4.35 (m, IH), 4.49 (m, 0.5H), 4.89 (m, 0.5H), 7.22-7.32 (m, 4H), 7.47 (d, 2H), 7.90-7.98 (m, 2.5H), 8.17 (s, (X5H), 9.88 (s, br, 0.5H), 10.20 (s, br, 0.5H); Anal. Calcd. for CzoH^NaOgS: C, 47.62; H, 3.80; N, 5.55. Found: C, 47.95; H, 4.03; N, 5.34. Example 22 1.2-dideoxv-2-fformvlfhvdroxv')aminoV3.4-Q-( 1-methvlethvlideneV 1 -((4-(4-(trifluoromethoxv)phenoxv)phenvl)sulfonvl)-L-threo-pentitol The desired product was prepared by substituting (2S,3S)-2,3-0-isopropylidine-2,3,4-trihydroxybutanal tert-butyldimethylsilyl ether (prepared by the procedure described in J. Org. Chem. 1993,v. 58, p. 5153) for (R)-2,2-diethyl-l,3-dioxolane-4-carboxaldehyde in Example 6A, then substituting the resulting product for Example 6A in Example 6B and Example 16B. MS (ESI) m/z 536 (M+H)+, 553 (M+NHO*; 'H NMR (400 MHz, DMSO-d6): 5 9.96 (s, 0.5H), 9.62 (s, 0.5H), 8.14 (s, 0.5H), 7.94-7.88 (m, 2H), 7.81 (s, 0.5H), 7.48-7.45 (m, 2H), 7.29-7.20 (m, 4H), 5.18-5.12 (m, IH), 4.72-4.62 (m, IH), 4.10-3.92 (m, 2H), 3.80-3.62 (m, 2H), 3.60-3.30 (m, 4H), 1.29-1.22 (m, 6H). 3 It will be evident to one skilled in the art that the instant invention is not limited to the forgoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within die meaning and range of equivalency of the claims and therefore intended to be embraced therein. We claim: 1. A compound of formula (I) having an activity to inhibit matrix metalloproteinases, or a pharmaceutically acceptable salt or prodrug thereof, wherein W1 is selected from the group consisting of (1) -O-, (2) -CH2O-, and (3) -CH2-; wherein each group is drawn with its left-hand end being the end which attaches to the carbon containing R1 and R2, and its right-hand end being the end which attaches to the carbon containing R3 and R4 ; X is selected from the group consisting of (1) -O, and (2) -N(R7)-, wherein R7 is selected from the group consisting of (a) hydrogen, (b) alkyl, (c) -SCValkyl, and (d) alkanoyl; R1 and R2 are independently selected from the group consisting of (1) hydrogen, (2) alkyl, and (3) hydroxyalkyl; R3 and R4 are independently selected from the group consisting of (1) hydrogen, and (2) alkyl, or R3 and R4 taken together are oxo, or R3 and R4, taken together with the carbon atom to which they are attached, form a cycloalkyl ring; R5 and R6 are independently selected from the group consisting of (1) hydrogen, (2) alkyl, (3) perfluoroalkyl, (4) halo, (5) haloalkyl, (6) alkoxy, (7) hydroxy, (8) hydroxyalkyl, (9) alkoxyalkyl, and (10) nitro; Y1 is selected from the group consisting of (1) a covalent bond, (2) -O-, (3) alkylene of two to four carbon atoms, (4) piperidineneyl, (5) alkenylene of two carbon atoms, (6) alkynylene of two carbon atoms, (7) -SO2-, and (8) -C(O)-; Ar is selected from the group consisting of (1) phenyl, (2) pyridyl, (3) pyrazinyl, (4) pyridazinyl, (5) furyl, (6) thienyl, (7) isoxazolyl, (8) oxazolyl, (9) thiazolyl and (10) isothiazolyl, wherein (1)- (10) can be optionally substituted with one, two, or three substituents independently selected from the group consisting of (a) alkyl, (b) alkoxy, wherein the alkoxy can be optionally substituted with alkoxy, (c) -(alkylene)-CO2R8, wherein R8 is either hydrogen or alkyl, (d) -(alkylene)-NR9R10 wherein R9 and R10 are independently selected from the group consisting of (i) alkyl (ii) phenyl, and (iii) phenylalkyl, wherein for (ii) and (iii), the phenyl and the phenyl part of the phenylalkyl can be optionally substituted with one or two substituents independently selected from the group consisting of halo and alkoxy, (e) alkoxyalkyl, (f) cyano, (g) cyanoalkyl, (h) halo, (i) haloalkyl, (j) hydroxy, (k) hydroxyalkyl, (1) thioalkoxy, (m) thioalkoxyalkyl, (n) phenylalkoxy, (o) phenoxy, (p) phenoxyalkyl, (q) (heterocycle) oxy, (r) (r) (heterocycle) oxyalkyl, (s) perfluoroalkyl, (t) perfluoroalkoxy, (u) sulfinylalkyl, (v) sulfonylalkyl, {-A\ B (w) {-O/ wherein A is selected from the group consisting of -CH2-,-CH20-and -O-, and B is selected from the group consisting of-C (O)- and- (C (R") i)v, wherein R" is either hydrogen or alkyl and v is 1-3, and (x) -N(R8)S02Rn, wherein R11 is selected from the group consisting of (i) hydrogen, (ii) alkyl, and (iii) -N(R8) (R12), wherein R12 is hydrogen or alkyl, wherein for (q) and (r), the heterocycle part of (heterocycle) oxy, and (heterocycle) oxyalkyl are selected from the group consisting of (i) pyridyl, (ii) pyrazinyl, (iii) pyridazinyl, (iv) furyl, (v) thienyl, (vi) isoxazolyl, (vii) oxazolyl, (viii) thiazoloyl, and (ix) isothiazolyl, and wherein for (q) and (r), the heterocycle part of the (heterocycle) oxy and the (heterocycle) oxyalkyl can be optionally substituted with one or two substituents independently selected from the group consisting of (i) alkyl, (ii) alkoxy, (iii) perfluoroalkyl, (iv) halo, (v) cyano, (vi) cyanoalkyl, (vii) haloalkyl, and (viii) alkanoyl, and wherein for (o) and (p), the phenyl part of the phenoxy and the phenoxyalkyl can be optionally substituted with one or two substituents independently selected from the group consisting of (i) alkyl, (ii) alkoxy, (iii) perfluoroalkyl, (iv) halo, (v) cyano, (vi) cyanoalkyl, (vii) haloalkyl, and (viii) alkanoyl. 2. A compound of formula I as claimed in claim 1, wherein Ar is phenyl. 3. A compound of formula I as claimed in claim 2, wherein Y1 is -O-. 4. A compound of formula I as claimed in claim 3, wherein W1 is-O-. 5. A compound of formula I as claimed in claim 4, wherein X is-O-. 6. A compound of formula I as claimed in claim 5 selected from the group consisting of (1 S)-l- ((4S)-2,2-dimethyl-1, 3-dioxolan-4-yl)-2- ((4-(4-(trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, (lR)-l-((4S)-2,2-dimethyl-l, 3-dioxolan-4-yl)-2-((4-(4-(trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, (lR)-l-( (4R)-2,2-dimethyl-l, 3-dioxolan-4-yl)-2- ((4- (4-(trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, (lS)-l-((4R)-2,2-dimethyl-l, 3-dioxolan-4-yl)-2-((4-(4-(trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, (lS)-l-((4S)-2,2-diethyl-l, 3-dioxolan-4-yl)-2- ((4- (4-(trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, l,4,5-trideoxy-4-(formyl(hydroxy)amino)-2,3-0-(l-methylethylidene)-5- ( (4- (4- (trifluoromethoxy) phenoxy) phenyl) sulfonyl)-D-xylitol, (lS)-l-((4S)-2,2-dimethyl-l, 3-dioxolan-4-yl)-2- ((4- (4-methoxyphenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, (lS)-2-((4-(4-chlorophenoxy) phenyl) sulfonyl)-l-((4S)-2, 2-dimethyl-l,3-dioxolan-4- yl) ethyl (hydroxy) formamide, (lS)-l-((4S)-2,2-dimethyl-l,3-dioxolan-4-yl)-2- ((4- (4-(trifluoromethyl) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, (1S)-1- ((4S)-2,2-dimethyl-l, 3-dioxolan-4-yl)-2- ((4- (4-methylphenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, (1S)-1-((4S)-1,3-dioxolan-4-yl)-2- ((4- (4- (trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, (lS)-l-((4S)-2,2-dimethyl-l, 3-dioxolan-4-yl)-2-((4-(4-(2-methoxyethoxy) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, and l,2-dideoxy-2-(formyl (hydroxy) arnino)-3,4-0-(l-methylethylidene)-l-((4-(4-(trifluoromethoxy) phenoxy) phenyl) sulfonyl)-L-threo-pentitol. A compound of formula I as claimed in claim 4, wherein X is-N (R7)-. A compound of formula I as claimed in claim 7 selected from the group consisting of hydroxy((lRS)-l-((4S)-2-oxo-l, 3-oxazolidin-4- yl)-2-((4-(4-(trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl) formamide and hydroxy((lRS)-l-((4S)-3-methyl-2-oxo-l, 3-oxazolidin-4-yl)-2-((4-(4- (trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl) formamide. A compound of formula I as claimed in claim 3, wherein W1is -CH2-. A compound of formula I as claimed in claim 9 wherein X is -O-. A compound according to Claim 10 selected from the group consisting of hydroxy((lS)-l-((2R)-tetrahydro-2-furanyl)-2-((4-(4-(trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl) formamide and hydroxy((lR)-l-((2R)-tetrahydro-2-furanyl)-2-((4-(4-(trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl) formamide. A compound of formula I as claimed in claim 9, wherein X is-N (R7)-. A compound of formula I as claimed in claim 12 which is hydroxy ((lS)-l-((2R)-l-(methylsulfonyl)pyrrolidinyl)-2-((4-(4-(trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl) formamide. A compound of formula I as claimed in claim 3, wherein W is-CH20-. 15. A compound of formula I as claimed in claim 14 which is l,2,4-trideoxy-2- (formyl (hydroxy) amino)-4,4-dimethyl-3,5-0- ( 1-methylethylidene)-l- ( (4-(4- (trifluoromethoxy) phenoxy) phenyl) sulfonyl)-D-threo-pentitol. 16. A compound of formula I as claimed in claim 2, wherein Y is a covalent bond, W1 is -O, and X is-O-. 17. A compound according to Claim 16 consisting of 4-chloro-4'-(((2S)-2- ((4S)-2,2-dimethyl-l,3-dioxolan-4-yl)-2-(formyl (hydroxy) amino) ethyl) sulfonyl)-l, l'-biphenyl, 4-(((2S)-2-((4S)-2,2-dimethyl-l,3-dioxolan-4-yl)-2- (formyl (hydroxy) amino) ethyl) sulfonyl)-4'-(trifluoromethyl)-l, l'-biphenyl, and 4- (((2S)-2-((4S)-2, 2-dimethyl-l,3-dioxolan-4-yl)-2-(formyl (hydroxy) amino) ethyl) sulfonyl)-4'- (2-methoxyethoxy)-l, l'-biphenyl. 18. A compound of formula I as claimed in claim 1, which is selected from the group consisting of (lS)-l-((4S)-2,2-dimethyl-l,3-dioxolan-4-yl)-2-((4-(4-(trifluoromethoxy)phenoxy)phenyl)sulfonyl)ethyl(hydroxy) formamide, (lR)-l-((4S)-2,2-dimethyl-l, 3-dioxolan-4-yl)-2- ((4-(4- (trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, (lR)-l-((4R)-2,2-dimethyl-l,3-dioxolan-4-yl)-2-((4-(4- (trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, (lS)-l-((4R)-2,2-dimethyl-l,3-dioxolan-4-yl)-2-((4-(4- (trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, 4-chloro-4'-(((2S)-2-((4S)-2,2-dimethyl-l,3-dioxolan-4-yl)-2- (formyl (hydroxy) amino) ethyl) sulfonyl)-!, l'-biphenyl, (lS)-l-((4S)-2,2-diethyl-l,3-dioxolan-4-yl)-2-((4-(4- (trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, l,4,5-trideoxy-4-(formyl(hydroxy)amino)-2,3-0-(l- methylethyhdene)-5-((4-(4-(trifluoromethoxy)phenoxy)phenyl) sulfonyl)-D-xylitol, (lS)-1-((4S)-2,2-dimethyl-l,3-dioxolan-4-yl)-2-((4-(4- methoxyphenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, (lS)-2-((4-(4-chlorophenoxy) phenyl) sulfonyl)-l-((4S)-2/ 2-dimethyl- 1,3-dioxolan-4- yl) ethyl (hydroxy) formamide, (lS)-l-((4S)-2,2-dimethyl-l, 3-dioxolan-4-yl)-2- ((4-(4- (trifluoromethyl)phenoxy)phenyl)sulfonyl)ethyl(hydroxy) formamide, (lS)-l-((4S)-2,2-dimethyl-l, 3-dioxolan-4-yl)-2- ((4- (4- methylphenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, 4-(({2S)-2-((4S)-2,2-dimethyl-l,3-dioxolan-4-yl)-2- (formyl (hydroxy) amino) ethyl) sulfonyl)'-rifluoromethyl)-1, 1'- biphenyl, (lS)-l-( (4S)-1,3-dioxolan-4-yl)-2- ((4- (4- (trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, 4-(((2S)-2-( (4S)-2,2-dimethyl-l,3-dioxolan-4-yl)-2- (formyl (hydroxy) amino) ethyl) sulfonyl)-4'- (2-methoxyethoxy)-L 1'-biphenyl, (lS)-l-((4S)-2,2-dimethyl-l,3-dioxolan-4-yl)-2-((4-(4-(2- methoxyethoxy) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide, l,2/4-trideoxy-2-(formyl(hydroxy)amino)-4,4-dimethyl-3,5-0-(l- methylethylidene)-l- ( (4--(4- (trifluoromethoxy) phenoxy) phenyl) sulfonyl)-D-threo-pentitol, hydroxy((lS)-l-((2R)-tetrahydro-2-furanyl)-2-((4-(4- (trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl) formamide, hydroxy ((lR)-l-((2R)-tetrahydro-2-furanyl)-2-((4-(4- (trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl) formamide, hydroxy ((lS)-l-((2R)-l-(methylsulfonyl) pyrrolidinyl)-2-((4-(4- (trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl) formamide, hydroxy ((lRS)-l-((4S)-2-oxo-l, 3-oxazolidin-4-yl)-2-((4-(4-(trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl) formamide, hydroxy((lRS)-l-((4S)-3-methyl-2-oxo-l,3-oxazolidin-4-yl)-2-((4-(4-(trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl) formamide, and l,2-dideoxy-2- (formyl (hydroxy) amino)-3,4-0-(l-methylethylidene)-l-((4-(4- (trifluoromethoxy) phenoxy) phenyl) sulfonyl)-L-threo-pentitol. 19. The compound of formula I as claimed in claim 1 which is (lS)-l-((4S)-2,2-dimethyl-l, 3-dioxolan-4-yl)-2- ((4- (4-(trifluoromethoxy) phenoxy) phenyl) sulfonyl) ethyl (hydroxy) formamide. Dated this 21st day of June 2001. Archana Shanker of Anand And Anand Advocates Attorney for the Applicant